NASDAQ:MRUSMerus Stock Price, Forecast & News

Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRUS stock has decreased by 2.8% and is now trading at $14.14. View which stocks have been most impacted by Coronavirus.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merus.

Merus is scheduled to release its next quarterly earnings announcement on Monday, August 17th 2020. View our earnings forecast for Merus.

Merus NV (NASDAQ:MRUS) announced its quarterly earnings data on Thursday, March, 12th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.60. The biotechnology company earned $7.09 million during the quarter, compared to analysts' expectations of $9.12 million. Merus had a negative net margin of 225.21% and a negative return on equity of 62.96%. View Merus' earnings history.

3 analysts have issued 12-month price targets for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they expect Merus' share price to reach $19.67 in the next twelve months. This suggests a possible upside of 39.1% from the stock's current price. View analysts' price targets for Merus.

News articles about MRUS stock have been trending positive on Friday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merus earned a news sentiment score of 2.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMerus.

Merus saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 227,600 shares, an increase of 6.1% from the April 30th total of 214,600 shares. Based on an average daily volume of 99,300 shares, the short-interest ratio is currently 2.3 days. Currently, 1.2% of the company's shares are short sold. View Merus' Current Options Chain.

Some companies that are related to Merus include Aurinia Pharmaceuticals (AUPH), Zymeworks (ZYME), Arvinas (ARVN), Corcept Therapeutics (CORT), Ligand Pharmaceuticals (LGND), Theravance Biopharma (TBPH), Ironwood Pharmaceuticals (IRWD), Zogenix (ZGNX), Heron Therapeutics (HRTX), Akebia Therapeutics (AKBA), Y-mAbs Therapeutics (YMAB), Opko Health (OPK), Arcus Biosciences (RCUS), CytoDyn (CYDY) and BELLUS Health (BLUSF). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merus investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Exelixis (EXEL), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Viking Therapeutics (VKTX), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP) and Fate Therapeutics (FATE).

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Merus' stock is owned by many different retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (6.25%), Driehaus Capital Management LLC (4.64%), Wellington Management Group LLP (2.91%), Cormorant Asset Management LP (2.07%), Morgan Stanley (0.57%) and Alps Advisors Inc. (0.18%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology. View institutional ownership trends for Merus.

MRUS stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Driehaus Capital Management LLC, Wellington Management Group LLP, Two Sigma Investments LP, Alps Advisors Inc., Athanor Capital LP, and Weiss Multi Strategy Advisers LLC. View insider buying and selling activity for Merus.

MRUS stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Morgan Stanley, Two Sigma Advisers LP, and Global Retirement Partners LLC. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology. View insider buying and selling activity for Merus.

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRUS stock can currently be purchased for approximately $14.14.

Merus has a market capitalization of $410.57 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

The official website for Merus is www.merus.nl.

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]